AR105534A1 - Sistema de suministro transdérmico - Google Patents
Sistema de suministro transdérmicoInfo
- Publication number
- AR105534A1 AR105534A1 ARP160102319A ARP160102319A AR105534A1 AR 105534 A1 AR105534 A1 AR 105534A1 AR P160102319 A ARP160102319 A AR P160102319A AR P160102319 A ARP160102319 A AR P160102319A AR 105534 A1 AR105534 A1 AR 105534A1
- Authority
- AR
- Argentina
- Prior art keywords
- patch
- dihydroetorphine
- supply system
- hydrate
- meth
- Prior art date
Links
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 229920000193 polymethacrylate Polymers 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000000151 deposition Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001012 protector Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un parche transdérmico que comprende: una capa que comprende (R)-dihidroetorfina, o una sal o un hidrato, y un poli(met)acrilato; y una capa de base. Reivindicación 29: Un método para elaborar un parche como el reivindicado en cualquiera de las reivindicaciones 1 a 28 que comprende: (i) depositar una composición que comprende (R)-dihidroetorfina, o una sal o un hidrato, y un poli(met)acrilato sobre una capa de base; (ii) evaporar ese solvente para formar una capa que contiene droga; y (iii) en forma opcional, aplicar un protector antiadherente a dicha capa que contiene droga. Reivindicación 31: Un parche transdérmico que comprende (R)-dihidroetorfina para su uso como un parche de 7 días. Reivindicación 34: Un método para el tratamiento del dolor en un sujeto que lo necesita que comprende la aplicación de un parche como el reivindicado en cualquiera de las reivindicaciones 1 a 28 ó 31 en la piel de ese sujeto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1513442.2A GB201513442D0 (en) | 2015-07-30 | 2015-07-30 | Transdermal patch |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105534A1 true AR105534A1 (es) | 2017-10-11 |
Family
ID=54062903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102319A AR105534A1 (es) | 2015-07-30 | 2016-07-29 | Sistema de suministro transdérmico |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180221298A1 (es) |
| EP (1) | EP3328432A1 (es) |
| JP (1) | JP6793718B2 (es) |
| KR (1) | KR20180031039A (es) |
| CN (1) | CN108136028A (es) |
| AR (1) | AR105534A1 (es) |
| AU (1) | AU2016298762A1 (es) |
| BR (1) | BR112018001564A2 (es) |
| CA (1) | CA2994109A1 (es) |
| GB (1) | GB201513442D0 (es) |
| IL (1) | IL256994A (es) |
| MA (1) | MA42522A (es) |
| MX (1) | MX2018001320A (es) |
| SG (1) | SG10201913253TA (es) |
| TW (1) | TW201707693A (es) |
| WO (1) | WO2017017453A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10231248A (ja) * | 1997-02-19 | 1998-09-02 | T T S Gijutsu Kenkyusho:Kk | ジヒドロエトルフィン含有経皮吸収型製剤 |
| US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| CN1780611B (zh) * | 2003-04-30 | 2013-01-30 | 珀杜医药公司 | 包括活性剂部分以及在活性剂层远侧的逆转剂的抗改造透皮剂型 |
| PE20081297A1 (es) * | 2003-04-30 | 2008-09-17 | Purdue Pharma Lp | Forma de dosificacion transdermica resistente a la manipulacion |
| DE102005011517A1 (de) * | 2005-03-10 | 2006-09-21 | Grünenthal GmbH | Transdermales therapeutisches System zur Verabreichung von Analgetika |
| TWI541246B (zh) * | 2008-12-08 | 2016-07-11 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
| GB201309654D0 (en) * | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
-
2015
- 2015-07-30 GB GBGB1513442.2A patent/GB201513442D0/en not_active Ceased
-
2016
- 2016-07-28 JP JP2018504675A patent/JP6793718B2/ja not_active Expired - Fee Related
- 2016-07-28 SG SG10201913253TA patent/SG10201913253TA/en unknown
- 2016-07-28 US US15/748,545 patent/US20180221298A1/en not_active Abandoned
- 2016-07-28 BR BR112018001564A patent/BR112018001564A2/pt not_active IP Right Cessation
- 2016-07-28 EP EP16747573.0A patent/EP3328432A1/en not_active Withdrawn
- 2016-07-28 CN CN201680055303.0A patent/CN108136028A/zh active Pending
- 2016-07-28 WO PCT/GB2016/052308 patent/WO2017017453A1/en not_active Ceased
- 2016-07-28 CA CA2994109A patent/CA2994109A1/en not_active Abandoned
- 2016-07-28 MA MA042522A patent/MA42522A/fr unknown
- 2016-07-28 KR KR1020187005892A patent/KR20180031039A/ko not_active Withdrawn
- 2016-07-28 MX MX2018001320A patent/MX2018001320A/es unknown
- 2016-07-28 AU AU2016298762A patent/AU2016298762A1/en not_active Abandoned
- 2016-07-29 TW TW105124075A patent/TW201707693A/zh unknown
- 2016-07-29 AR ARP160102319A patent/AR105534A1/es unknown
-
2018
- 2018-01-18 IL IL256994A patent/IL256994A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180221298A1 (en) | 2018-08-09 |
| CA2994109A1 (en) | 2017-02-02 |
| MX2018001320A (es) | 2018-08-15 |
| KR20180031039A (ko) | 2018-03-27 |
| AU2016298762A1 (en) | 2018-02-15 |
| GB201513442D0 (en) | 2015-09-16 |
| IL256994A (en) | 2018-03-29 |
| BR112018001564A2 (pt) | 2018-09-18 |
| WO2017017453A1 (en) | 2017-02-02 |
| JP6793718B2 (ja) | 2020-12-02 |
| EP3328432A1 (en) | 2018-06-06 |
| SG10201913253TA (en) | 2020-03-30 |
| MA42522A (fr) | 2018-06-06 |
| TW201707693A (zh) | 2017-03-01 |
| CN108136028A (zh) | 2018-06-08 |
| JP2018528176A (ja) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX382471B (es) | Parche de microagujas para administrar un ingrediente activo a la piel. | |
| DK3902547T3 (da) | Csf1r-hæmmere til anvendelse i cancerbehandling | |
| CL2017003404A1 (es) | Compuestos antibacterianos | |
| MX386427B (es) | Sistemas y métodos para cicatrización de tejido. | |
| PT3661514T (pt) | Mavacamten para utilização no tratamento da cardiomiopatia hipertrófica | |
| MX2019007391A (es) | Sistema terapeutico transdermico que contiene asenapina. | |
| MX2016011744A (es) | Soluciones de buprenorfina de liberacion sostenida. | |
| CR20150360A (es) | Sistema de liberación transdérmica | |
| UY36135A (es) | ?un método para la fabricación de un material de superficie modificada, un material de superficie modificada y su uso? | |
| CL2018001171A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| MX2019007389A (es) | Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno. | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| ZA201902275B (en) | Topical dressing composition for the treatment of damaged skin tissue | |
| EP3572095A4 (en) | Pharmaceutical composition used for treatment of htlv-1-associated myelopathy | |
| PL3732294T3 (pl) | Tymohydrochinon do stosowania w leczeniu hiperglikemii | |
| MX2016014859A (es) | Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas. | |
| MX387410B (es) | Composiciones y metodos para el tratamiento y profilaxis de infecciones del sitio quirurgico | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| TR201905392T4 (tr) | Ağrı tedavisi. | |
| CO2018001831A2 (es) | Composición de absorción percutánea en forma de parche | |
| CR20150044A (es) | Formulación transdérmica que contiene inhibidores de cox | |
| EP3500192C0 (en) | TREATMENT DEVICE FOR SELECTIVE TISSUE REMOVAL | |
| MX2016014701A (es) | (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina. | |
| MX2015010967A (es) | Formulaciones transdermicas de laquinimod. | |
| AR105534A1 (es) | Sistema de suministro transdérmico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |